Articles tagged with Flu Vaccines
NIAID has awarded eight contracts to strengthen and expand its VTEUs, which will carry out more clinical trials in larger populations and safely test vaccines in specific vulnerable populations. The units will have inpatient beds for isolating volunteers, making it easier to conduct trials quickly.
A study found that nearly a quarter of cancer patients receiving radiation therapy are not getting vaccinated against flu and pneumonia, posing a significant risk to their health. Oncologists can play a key role in informing patients about recommended vaccines during regular interactions.
Researchers found that influenza vaccine was more effective in a semi-urban population than in a rural population of schoolchildren in Gabon, Africa. Infection with parasites and/or poor nutrition may compromise immune responses to the flu vaccine.
Researchers found that influenza vaccine is less effective in rural children of Gabon compared to semi-urban counterparts due to co-infections and poor nutrition. This study highlights the need for tailored approaches to pandemic influenza prevention in developing countries.
A new flu vaccine delivered through painless microneedles in patches applied to the skin could soon be an alternative to hypodermic needles, offering less discomfort and lower costs. The Emory University and Georgia Institute of Technology team aims to design patches that can increase immunity to influenza with smaller amounts of vaccine.
Researchers at Texas A&M University are developing an aloe vera-based nosespray vaccine that has shown promising results in animal trials. The vaccine uses a gel-like substance to cling to the inside of the nose, allowing it to stay longer and work more effectively than traditional liquid sprays.
The Lancet Infectious Diseases report highlights frailty selection bias and non-specific trial endpoints as reasons behind the exaggeration. Few trials have included elderly people, especially those aged at least 70 years, which accounts for three-quarters of all influenza-related deaths.
Researchers from NIH identify sources of bias in previous studies, suggesting strategies to reduce severe influenza outcomes among the elderly. The authors emphasize the need for better flu vaccines and new approaches, including antiviral drugs and targeted vaccination for high-risk individuals.
A new study published in Pediatrics found that annual flu shots significantly reduce outpatient visits and hospitalizations due to flu-related illness. Vaccinating half of U.S. children could prevent up to 650,000 doctor's office visits and 2,250 hospitalizations per year.
Researchers developed a novel antigen-sparing adjuvant strategy to improve immunogenicity of the bird flu vaccine. The new formulation showed significant cross-clade immunity against H5N1 viruses and induced high levels of neutralizing antibodies, increasing protection against pandemic.
A new study by the New York Academy of Medicine highlights the critical need to address vaccination coverage among hard-to-reach populations. The authors propose achievable strategies to increase immunization rates among these groups, including unconventional site distribution and patient reminders.
A national survey found gaps in vaccine financing for underinsured children, leading to concerns about access to life-saving vaccinations like pneumococcal conjugate and meningococcal conjugate vaccines. The study highlights the need for improved funding and distribution of new pediatric vaccines at the state level.
Researchers at The Wistar Institute discovered a mechanism where the gene-transcription machinery can be paused by the ubiquitin molecule until a triggering signal is received. This pause allows for quick activation of genes in response to stress or vital needs, such as stem-cell differentiation.
Two new studies emphasize the importance of delivering measles and influenza vaccines to HIV-infected individuals. Measles vaccine administered at age 9 months showed limited protection in HIV-infected children, highlighting the need for supplementary vaccinations to maintain immunity. In contrast, rates of influenza vaccination among ...
Scientists are testing a universal flu vaccine that targets all 'A' strains of the virus, offering broad and lifelong protection. The vaccine has shown promising results in laboratory animals and is now being administered to a small group of healthy people in Phase I clinical trials.
A study predicts that using Tamiflu prophylactically could reduce illness and death rates during an influenza pandemic by half, with a cost savings of $70,000 per 1,000 population. Prophylaxis with antivirals or vaccines is considered a crucial strategy in the early months of a pandemic.
Researchers detected anti-Fluzone antibodies in 40% of cord blood specimens, establishing B and T cell responses to antigens occur in utero following maternal vaccination. This finding has significant implications for understanding when immune responses to environmental exposures begin.
Research highlights the influence of private hospital care on Medicaid patients, flu vaccine shortages, and smoking bans on health outcomes. Smoking bans at home and work significantly improve health status among nonsmokers, while racial diversity in neighborhoods affects pregnant women's decision to smoke.
Current health policy based on voluntary vaccinations is not enough to control severe flu epidemics and pandemics unless vaccination programs offer incentives to individuals. Free vaccinations for entire families could actually increase the frequency of severe epidemics, according to UCLA researchers.
A new study by UCLA researchers suggests that current US control strategies for flu epidemics may not be effective and could even make outbreaks worse. The study found that providing free vaccinations to entire families can actually increase the frequency of severe epidemics due to decreased adaptability among household members.
A national study led by Saint Louis University School of Medicine is investigating the effectiveness of a new investigational vaccine made by Bavarian Nordic in stimulating an immune response against smallpox. The study aims to determine how quickly people can be protected after a release of smallpox into the environment.
Research shows that influenza epidemics are associated with a rise in deaths from heart disease and flu can trigger heart attacks. The study highlights the importance of increasing vaccination rates in people at risk of coronary heart disease.
A new experimental flu vaccine made in insect cells has been shown to be safe and effective in protecting against the flu, with a stronger immune response at higher doses. The use of cell culture systems to grow vaccines is a growing business and could potentially slice off months from the production process.
A new experimental flu vaccine produced using insect cells has shown promising results in early testing, demonstrating safety and immunogenic response in healthy adults. The vaccine, made using recombinant DNA techniques, offers a potential alternative to traditional egg-based vaccines.
The University of Rochester Medical Center has been awarded a $26 million contract to establish the New York Influenza Center of Excellence, one of six nationwide centers focused on improving flu research. The center aims to develop more effective vaccines against seasonal influenza and future pandemics.
Historical analyses of the 1918 Spanish influenza pandemic reveal that cities with early public health measures had lower peak weekly death rates and overall mortality compared to those that waited. Implementing multiple social containment measures within a few days of first local cases recorded cut peak death rates by up to half.
A new UCLA study found that practicing Tai Chi chih alone boosts immunity to a level comparable to the standard vaccine against shingles. Combining Tai Chi with the vaccine results in a clinically relevant boost and added benefits for middle-aged adults.
Developing an H5 vaccine faces hurdles in current egg production methods and the molecule's ability to stimulate an immune reaction, requiring two shots for full immunization. The ideal adjuvant must still be found to boost vaccine effectiveness.
Developing countries face a critical shortage of pandemic influenza vaccines, with only 500 million doses available globally. The WHO is urging international agreement to ensure affordable vaccine access for these nations, demonstrating global solidarity in the face of the next pandemic threat.
A recent global study found that a nasal spray flu vaccine reduced the attack rate of flu in children by 55 percent compared to traditional flu shots. The vaccine was well-tolerated and induced a more complete immune response, with fewer ear infections reported.
Researchers at St. Jude Children's Research Hospital found that the N1 protein in seasonal flu vaccines can trigger an antibody response to avian flu virus, offering cross-protection to some individuals. The study suggests that annual influenza vaccines may be beneficial to populations in areas where H5N1 poses a threat to humans.
A human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began in December 2006. The vaccine instructs human cells to make proteins that act as a vaccine against the virus, providing broad immune responses without infectious material.
A futures market for influenza activity has been created, predicting outbreaks two to four weeks in advance with high accuracy. The market aggregates expert opinions of healthcare providers, allowing for real-time analysis and informed decision-making in public health.
A University of Michigan study found that the traditional flu shot was effective in preventing influenza in healthy adults, while the live attenuated-virus nasal spray vaccine was less effective. The study compared the two vaccines head-to-head with laboratory confirmation and found significant differences in their protective effects.
The 2004 influenza vaccine shortage had a significant impact on continuity of care, with flu vaccination rates dropping by over 50% in some areas. Additionally, studies found that improper antibiotic use can exacerbate sinusitis symptoms and that patients with sore throats often seek pain relief rather than antibiotics.
A federal plan to vaccinate healthcare workers against smallpox had a low compliance rate and high variability among states. Researchers found that some states ranked poorly due to lack of support and ambivalent messages from authorities.
A powerful analysis reveals that only one-third of high-risk populations in Europe receive seasonal influenza vaccine, resulting in avoidable morbidity and mortality. Implementing EU vaccination recommendations could reduce the number of cases of death and illness from influenza, as well as contribute to flu pandemic preparedness.
The U.S. Vaccine and Infectious Disease Organization has discovered a crucial pathway that supports the influenza A virus's ability to reproduce itself. This finding could lead to the development of new live vaccines and antiviral drugs for influenza epidemics and pandemics.
A RAND Corporation study found that nursing homes with high staff and resident vaccination rates are less likely to experience flu outbreaks. Vaccination rates of over 55% for staff and 89% for residents were associated with a 60% reduction in influenza-like illness cases.
A Canadian study found that flu vaccines are associated with a small but increased risk of hospitalization for Guillain-Barré syndrome, a potentially debilitating neurological disorder. The absolute risk is very low, and the disorder affects about one in 100,000 individuals per year.
A large safety study found that the flu vaccine is not associated with an increased risk of serious conditions in young children. The study analyzed data on over 45,000 children who received the trivalent inactivated influenza vaccine between 1991 and 2003.
Scientists have developed a vaccine that protects mice against the 1918 influenza virus, which killed 50 million people worldwide. The vaccine works by stimulating antibodies capable of neutralizing the virus, providing a potential solution to future pandemic flu strains.
A booster shot given before a primary immunization may protect people against bird flu. Studies in Rochester suggest that adults who have never encountered the virus would benefit from an additional dose.
Researchers found that a prime-boost strategy using different subtypes of H5N1 vaccines significantly boosted immune responses in individuals with prior exposure. Additionally, an intradermal approach to delivering the vaccine showed promise but did not improve the immune response. These findings suggest pre-pandemic priming with exist...
The Journal of Infectious Diseases has published a supplement offering current information on pandemic and seasonal influenza, featuring leading experts discussing research and recommendations. The article highlights key findings on disease surveillance, vaccine manufacturing, and public health response plans.
A new study by mathematical biologists at The University of Texas at Austin recommends vaccine distribution strategies for potential shortages. The best approach depends on the contagiousness of the flu strain, with school children and high-risk groups being prioritized accordingly.
Researchers found that KEAP1 mutations in lung cancer cells increase NRF2 activity, leading to chemotherapy resistance. Meanwhile, a new study suggests targeting school-aged children for flu vaccination could help contain outbreaks.
A clinical trial has demonstrated the efficacy of an H9N2 avian flu vaccine combined with an adjuvant in generating a strong antibody response in humans. The results suggest that even low doses of the vaccine can provide protection, making it a promising tool in pandemic prevention.
Researchers have achieved effective immunity with a low dose of bird flu vaccine using MF59 adjuvant, potentially stretching vaccine supply. The study showed that antibody levels were significantly better and that a single dose of the adjuvanted vaccine was as good as two doses without adjuvant.
Researchers propose using existing facilities to produce vaccines from cell cultures, which could make enough doses to cover the US in just 3-4 months. This approach would reduce downtime and capital investments required for new dedicated facilities.
Researchers developed live attenuated vaccines using weakened influenza virus proteins and found they elicited broad and lasting immunity in mice and ferrets. The vaccines provided protection against different H5N1 viruses that emerged years later, demonstrating potential as a future treatment option for avian flu.
A new H5N1 influenza vaccine has produced a safe and effective immune response in healthy people at low doses, with the highest dose showing the best response. The vaccine was well-tolerated and did not have significantly more side effects compared to a placebo.
The University of Pittsburgh School of Medicine has received a $1.3 million grant to produce a promising avian flu vaccine that could protect against the deadly H5N1 virus. The vaccine, developed by Dr. Andrea Gambotto's team, has shown complete protection in mice and chickens against infection.
Researchers at MSU have developed a new cell line that can grow nearly all types of flu viruses, potentially leading to faster and cheaper vaccine production. This could help address the issues with traditional influenza vaccine production methods, including long production times and limited supply.
A new H5N1 vaccine has demonstrated cross-protection in ferrets against different variants of the virus, offering a promising solution for stockpiling in the event of a human outbreak. The vaccine was shown to completely protect ferrets from infection and reduce viral multiplication.
A new experimental vaccine has shown significant protective effects against multiple H5N1 strains in lab animals. The two-dose vaccination schedule induced higher levels of antibodies that were cross-reactive to various viruses, suggesting a potential solution for stockpiling vaccines during pandemics.
Researchers suggest that cholesterol-lowering drugs like statins could be useful in treating and preventing severe complications of the flu during a pandemic. Statins have anti-inflammatory and immunomodulatory effects that may also benefit people with influenza, making them a potential alternative to vaccines.
Researchers report improved survival rates with RP101, a novel compound being investigated as a potential therapeutic for advanced pancreatic cancer. In two studies, patients showed significant improvements in median survival and time to progression, offering hope for patients affected by the disease.
A new study explores how people make medical decisions, revealing that stepping into others' shoes can lead to better choices. By considering multiple perspectives, including those of doctors, parents, and medical directors, participants made treatment decisions that were more informed than their own self-interest would suggest.
A study found that higher dose flu vaccines significantly enhanced protection against naturally occurring influenza, increasing immunogenicity in the elderly. The research also showed that all three vaccine dosage levels were safe and well-tolerated.